articles
all the news
Results for the 2nd Quarter 2019
- FOLLOWING THE FAILURE OF OUR APPLICATION FOR A EUROPEAN SUBSIDY, ONE OF OUR SHAREHOLDER COMMITS TO RAISE THE BUDGET FOR PROOF OF EFFICACY - CC & C RECEIVES DELIVERANCE OF ITS PATENT FOR JAPAN AND THE USA On June 20th, we received the notification of rejection of...
read moreResults for the 1st Quarter 2019
- SHAREHOLDERS TO APPROVE TOD FINANCES' INVESTMENT IN CC&C - CC & C GETS CERTIFICATION BY ITS COMPETITIVENESS CLUSTER We held our General Assembly on May 9th.This was mainly an opportunity to ratify family office “TOD Finances” investment in the company....
read moreResults for the 4th quarter 2018
- PARTICIPATION IN CC & C - NEWS OF OUR RESEARCH PROJECTS TOD Finances, a french family office, is expected to invest 100,000 euros in our company by the end of February. This excellent news will allow us to hire a new researcher and launch new projects. In...
read moreResults for the 3rd quarter 2018
- RESULTS OF THE CALL FOR EUROPEAN PROJECTS FET-OPEN - A NEW RESEARCH PROJECT WITH THE UNIVERSITY OF MONTPELLIERWe have received the answer from the European Commission: unfortunately, it is negative. However, we get a very good grade, and the comments of the...
read more
Proof of efficacy for dummies
This article is for curious but unscientific readers. Expert readers will find a description of the planned protocol within the NanoStress consortium here. For 2 years, we have announced everywhere that to obtain our Proof of Efficacy will mark the...
read more
A joint experiment between CC&C and the IBDM
- Mechanical Signals and Cancer: a new experiment on colon cancer. First results expected early 2019. Based in Marseille, the IBDM brings together about twenty research teams that explore the field of developmental biology and associated pathologies, with daily...
read more
Results for the second quarter 2018
- EUROPEAN GRANT APPLICATION FET OPEN: 1.8 MILLION EURO REQUESTED, RESPONSE ON OCTOBER 16TH, 2018 - AFTER STANFORD UNIVERSITY, NEW PARTNERSHIPS IN PERSPECTIVE On May 16th, we submitted an application for a grant of 1.8 million Euro from the European Commission as part...
read more
20 months of extra life for pancreatic cancer patients
In Chicago, on June 4th, was held the annual conference of the American Society of Clinical Oncology (ASCO), during which an interesting communication was made. The news comes from France, more precisely from Nancy. Already three years ago, the team of the Cancer...
read more
NanoStress: we answered the FET-Open call for projects
The FET-Open call of the European Commission finances disruptive innovation research projects capable of « changing the world ». We did not need it any less, so we submitted today a nomination file within the NanoStress consortium, in order to obtain the Proof of...
read more
Results for the first quarter 2018
- WITH THE SUPPORT OF INSERM, GET EUROPEAN FUNDS - LAST FUNDRAISE BEFORE CHANGING OUR FUNDING MODEL The FET-Open call for projects, which is part of the Horizon 2020 program for research initiated by the European Commission, selects its laureates for...
read more
In vivo: Proof of Efficacy
The principles The possibility of therapeutic use, of course, opens up enormous opportunities. The method fits into the current conception of carcinogenesis: impossibility of thinking the cancerous transformation without integrating the interaction Extra Cellular...
read more
Cancer a Genetic or Mechanical Disease?
"Mechanical signals play a vital role in cancer .... " This is a phrase that appears at the beginning of thousands of scientific articles, and more and more since 2005 date of the first article showing their importance in oncology (M Paszek, 2005). But for 60 years it...
read more
Pancreatic Cancer: a decisive partnership with Stanford University by 2018
French start-up Cell Constraint & Cancer joins forces with one of the largest American Universities to find new therapeutic solutions for pancreatic cancer. "Year 2018 marks a turning point in the life of our company. Obtaining our Proof of Effeciency on...
read more
About our trip to San Francisco
CC & C was honored to be one of the 3 high-tech start-ups selected in the 2017 NETVA program. As a reminder, NETVA, for New Technology Venture Accelarator, is a program sponsored by the French Embassy in Washington to develop scientific and industrial exchanges...
read more
More than 2.900 readers of our article !
It is a more than respectable score for a prose, it must be admitted, rather arid. Especially as the number of readers continues to increase steadily, while it was published more than a year ago. One more sign that physical oncology is gradually making its way into...
read more
Brief feedback on our trip to San Francisco, under the NETVA program – nov 2017
Rémy Brossel, CSO of Cell Constraint & Cancer went to present our technology in San Francisco and in the Bay Area, thanks to the support of the french Embassy. Contacts were made in particular with a (very) big university of the Bay for our project "Action of a...
read more
“Physical Oncology” is entering Wikipedia
A new step in the recognition of physical oncology: a page on the subject has just been created in Wikipedia! Check it here: https://en.wikipedia.org/wiki/Physical_oncology
read more
Our executive summary 2018
Our Executive Summary is updated. This version becomes our reference document for the year 2018. Do not hesitate to download it : Executive Summary anglais -...
read more
Imaging the Force of Cancer: A European H2020 Program
The existence of this program is great news for anyone who believes in the future of applying the laws of physics and the use of mechanical signals in oncology. Europe supports a consortium of 16 participants that aims to image and to measure the active forces in a...
read more
Our Exececutive Summary for 2017
Our revised Executive Summary was just released. It will become our reference document for the period 2017-2018. Please download it here:...
read more
After the failure of targeted therapies, what to propose?
About the article "Targeted therapies against cancer fall short of the hopes raised" by Professor Ian Tannock of the University of Toronto, Canada. In this article, originally published in the prestigious New England Journal of Medicine, and then in Le Monde,...
read more
Status of our research
Plans of animal demonstrator completed Thanks to Christian Chillet, of the G2ELab, our partner on superconducting magnets, our working hypotheses on the feasibility of the experimental device of the Proof of Efficiency are validated. Mr. Chillet gave us the...
read more
Rémy Brossel will be in San Francisco in october, thanks to the Netva Programm
CC & C was selected to participate in October 2017 in a presentation of our activities in California under the NETVA program. The NETVA program (New Technology Venture Accelerator) offers young innovative startups in France a personalized support program, analysis...
read morearticles
all the news
Results for the 2nd Quarter 2019
- FOLLOWING THE FAILURE OF OUR APPLICATION FOR A EUROPEAN SUBSIDY, ONE OF OUR SHAREHOLDER COMMITS TO RAISE THE BUDGET FOR PROOF OF EFFICACY - CC & C RECEIVES DELIVERANCE OF ITS PATENT FOR JAPAN AND THE USA On June 20th, we received the notification of rejection of...
read moreResults for the 1st Quarter 2019
- SHAREHOLDERS TO APPROVE TOD FINANCES' INVESTMENT IN CC&C - CC & C GETS CERTIFICATION BY ITS COMPETITIVENESS CLUSTER We held our General Assembly on May 9th.This was mainly an opportunity to ratify family office “TOD Finances” investment in the company....
read moreResults for the 4th quarter 2018
- PARTICIPATION IN CC & C - NEWS OF OUR RESEARCH PROJECTS TOD Finances, a french family office, is expected to invest 100,000 euros in our company by the end of February. This excellent news will allow us to hire a new researcher and launch new projects. In...
read moreResults for the 3rd quarter 2018
- RESULTS OF THE CALL FOR EUROPEAN PROJECTS FET-OPEN - A NEW RESEARCH PROJECT WITH THE UNIVERSITY OF MONTPELLIERWe have received the answer from the European Commission: unfortunately, it is negative. However, we get a very good grade, and the comments of the...
read moreProof of efficacy for dummies
This article is for curious but unscientific readers. Expert readers will find a description of the planned protocol within the NanoStress consortium here. For 2 years, we have announced everywhere that to obtain our Proof of Efficacy will mark the...
read moreA joint experiment between CC&C and the IBDM
- Mechanical Signals and Cancer: a new experiment on colon cancer. First results expected early 2019. Based in Marseille, the IBDM brings together about twenty research teams that explore the field of developmental biology and associated pathologies, with daily...
read moreResults for the second quarter 2018
- EUROPEAN GRANT APPLICATION FET OPEN: 1.8 MILLION EURO REQUESTED, RESPONSE ON OCTOBER 16TH, 2018 - AFTER STANFORD UNIVERSITY, NEW PARTNERSHIPS IN PERSPECTIVE On May 16th, we submitted an application for a grant of 1.8 million Euro from the European Commission as part...
read more20 months of extra life for pancreatic cancer patients
In Chicago, on June 4th, was held the annual conference of the American Society of Clinical Oncology (ASCO), during which an interesting communication was made. The news comes from France, more precisely from Nancy. Already three years ago, the team of the Cancer...
read moreNanoStress: we answered the FET-Open call for projects
The FET-Open call of the European Commission finances disruptive innovation research projects capable of « changing the world ». We did not need it any less, so we submitted today a nomination file within the NanoStress consortium, in order to obtain the Proof of...
read moreResults for the first quarter 2018
- WITH THE SUPPORT OF INSERM, GET EUROPEAN FUNDS - LAST FUNDRAISE BEFORE CHANGING OUR FUNDING MODEL The FET-Open call for projects, which is part of the Horizon 2020 program for research initiated by the European Commission, selects its laureates for...
read moreIn vivo: Proof of Efficacy
The principles The possibility of therapeutic use, of course, opens up enormous opportunities. The method fits into the current conception of carcinogenesis: impossibility of thinking the cancerous transformation without integrating the interaction Extra Cellular...
read moreCancer a Genetic or Mechanical Disease?
"Mechanical signals play a vital role in cancer .... " This is a phrase that appears at the beginning of thousands of scientific articles, and more and more since 2005 date of the first article showing their importance in oncology (M Paszek, 2005). But for 60 years it...
read morePancreatic Cancer: a decisive partnership with Stanford University by 2018
French start-up Cell Constraint & Cancer joins forces with one of the largest American Universities to find new therapeutic solutions for pancreatic cancer. "Year 2018 marks a turning point in the life of our company. Obtaining our Proof of Effeciency on...
read moreAbout our trip to San Francisco
CC & C was honored to be one of the 3 high-tech start-ups selected in the 2017 NETVA program. As a reminder, NETVA, for New Technology Venture Accelarator, is a program sponsored by the French Embassy in Washington to develop scientific and industrial exchanges...
read moreMore than 2.900 readers of our article !
It is a more than respectable score for a prose, it must be admitted, rather arid. Especially as the number of readers continues to increase steadily, while it was published more than a year ago. One more sign that physical oncology is gradually making its way into...
read moreBrief feedback on our trip to San Francisco, under the NETVA program – nov 2017
Rémy Brossel, CSO of Cell Constraint & Cancer went to present our technology in San Francisco and in the Bay Area, thanks to the support of the french Embassy. Contacts were made in particular with a (very) big university of the Bay for our project "Action of a...
read more“Physical Oncology” is entering Wikipedia
A new step in the recognition of physical oncology: a page on the subject has just been created in Wikipedia! Check it here: https://en.wikipedia.org/wiki/Physical_oncology
read moreOur executive summary 2018
Our Executive Summary is updated. This version becomes our reference document for the year 2018. Do not hesitate to download it : Executive Summary anglais -...
read moreImaging the Force of Cancer: A European H2020 Program
The existence of this program is great news for anyone who believes in the future of applying the laws of physics and the use of mechanical signals in oncology. Europe supports a consortium of 16 participants that aims to image and to measure the active forces in a...
read moreOur Exececutive Summary for 2017
Our revised Executive Summary was just released. It will become our reference document for the period 2017-2018. Please download it here:...
read moreAfter the failure of targeted therapies, what to propose?
About the article "Targeted therapies against cancer fall short of the hopes raised" by Professor Ian Tannock of the University of Toronto, Canada. In this article, originally published in the prestigious New England Journal of Medicine, and then in Le Monde,...
read moreStatus of our research
Plans of animal demonstrator completed Thanks to Christian Chillet, of the G2ELab, our partner on superconducting magnets, our working hypotheses on the feasibility of the experimental device of the Proof of Efficiency are validated. Mr. Chillet gave us the...
read moreRémy Brossel will be in San Francisco in october, thanks to the Netva Programm
CC & C was selected to participate in October 2017 in a presentation of our activities in California under the NETVA program. The NETVA program (New Technology Venture Accelerator) offers young innovative startups in France a personalized support program, analysis...
read more